Skip to content

Retrospective study to understand the patient profile and prescribing pattern for amlodipine and its combinations in patients with primary hypertension.

Retrospective, EMR study to understand usage pattern, and profile of patients prescribed with amlodipine and its combinations - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/09/057949
Enrollment
8000
Registered
2023-09-22
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: nil: nil

Sponsors

Dr Reddys Laboratories Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: EMR records of patients =18 years of age • EMR records of patients with “clinically diagnosed as primary hypertensive ? • EMR records of patients prescribed with amlodipine or its combinations with or without other antihypertensive agents in any visit other than the first visit on EMR platform. • EMR records of patients with a follow up within 10-30 days from prescription of amlodipine/its combinations.

Exclusion criteria

Exclusion criteria: Patients with hypertension due to secondary reasons – viz. pregnancy induced hypertension. • Patients with incomplete data on EMR platform.

Design outcomes

Primary

MeasureTime frame
To study the prescription pattern of amlodipine and its combinations in patients with different patient profiles and clinical features and comorbidities like diabetes mellitus, chronic kidney disease, coronary artery disease and other cardiac diseases and stroke at baseline in EMR records.Timepoint: Outcome analysis will be done for the patients who have a follow up visit within 10-30 days from prescription of amlodipine or its combinations

Secondary

MeasureTime frame
To assess the change in SBP and DBP from baseline (index date) to follow-up in all the patients (with/without any comorbid condition). • To assess the incidence of pedal edema. • To evaluate percentage of patients who achieved target blood pressure at follow up.Timepoint: Data will be captured for one consecutive follow-up visit within 10-30 days from the baseline visit/index date

Countries

India

Contacts

Public ContactDr Rahul Rathod

Dr Reddys Laboratories Limited

mujtabanaqvi@drreddys.com7032969523

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026